

QUANTITY LIMIT CRITERIA

DRUG CLASS	SHORT ACTING BETA2-ADRENERGIC AGONIST, COMBINATION ORAL INHALATION
-------------------	---

BRAND NAME (generic)	AIRSUPRA (albuterol and budesonide inhalation aerosol) (albuterol inhalation solution) PROAIR DIGIHALER (albuterol) PROAIR HFA (albuterol) PROAIR RESPICLICK (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX SOLUTION (levalbuterol) XOPENEX CONCENTRATE (levalbuterol) XOPENEX HFA (levalbuterol)
---------------------------------	--

Status: CVS Caremark® Criteria
Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Airsupra

Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Beta Agonists-Short Acting, Combination Oral Inhalation Limit Policy 1086-H 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-584281 021423

Albuterol Sulfate Inhalation Solution 0.63 mg/3 mL and 1.25 mg/3 mL

Albuterol Sulfate Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).

Albuterol Sulfate Inhalation Solution 0.083% (2.5 mg/3 mL)

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

Albuterol Sulfate Inhalation Solution 0.5% (2.5 mg/0.5 mL)0.5 mL Vial

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

20 mL Bottle

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

ProAir DigihalerBronchospasm

ProAir Digihaler is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

ProAir HFABronchospasm

ProAir HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Proair HFA Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

ProAir RespiclickBronchospasm

ProAir Respiclick is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Respiclick is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Proventil HFA

Proventil HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Ventolin HFABronchospasm

Ventolin HFA is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Ventolin HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.

Xopenex Solution

Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex Concentrate

Xopenex (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex HFA

Xopenex HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

INITIAL LIMIT CRITERIA

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

Medication*	Maintenance Dose	Maximum Daily Dose	Package Size	1 Month Limit* 3 Month Limit*
Airsupra (albuterol and budesonide)	2 inhalations as needed	12 inhalations	120 inhalations per 10.7 gm canister	3 packages (10.7 gm each) / 25 days 9 packages (10.7 gm each) / 75 days
Albuterol 0.63 mg/3 mL, 1.25 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	25 vials (3 mL each) per carton	5 packages (125 vials x 3 mL) / 25 days 15 packages (375 vials x 3 mL) / 75 days
			30 vials (3 mL each) per carton	4 packages (120 vials x 3 mL) / 25 days 12 packages (360 vials x 3 mL) / 75 days
Albuterol 0.083%, 2.5 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	25 vials (3 mL each) per carton	5 packages (125 vials x 3 mL) / 25 days 15 packages (375 vials x 3 mL) / 75 days
			30 vials (3 mL each) per carton	4 packages (120 vials x 3 mL) / 25 days 12 packages (360 vials x 3 mL) / 75 days
			60 vials (3 mL each) per carton	2 packages (120 vials x 3 mL) / 25 days 6 packages (360 vials x 3 mL) / 75 days
Albuterol 0.5%, 2.5 mg/0.5 mL Inhalation Solution	nebulization of 0.25 mL-0.5 mL three to four times daily	2 mL	20 mL per bottle	3 packages (20 mL each) / 25 days 9 packages (20 mL each) / 75 days
			30 vials (0.5 mL each) per carton	4 packages (120 vials x 0.5 mL) / 25 days 12 packages (360 vials x 0.5 mL) / 75 days
ProAir Digihaler (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per inhaler	2 packages / 25 days 6 packages / 75 days
ProAir HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 8.5 gm canister	2 packages (8.5 gm each) / 25 days 6 packages (8.5 gm each) / 75 days
ProAir RespiClick (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per inhaler	2 packages / 25 days 6 packages / 75 days
Proventil HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 6.7 gm canister	2 packages (6.7 gm each) / 25 days 6 packages (6.7 gm each) / 75 days
Ventolin HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	60 inhalations per 8 gm canister	6 packages (8 gm each) / 25 days 18 packages (8 gm each) / 75 days
			200 inhalations per 18 gm canister	2 packages (18 gm each) / 25 days 6 packages (18 gm each) / 75 days
Xopenex 0.31 mg, 0.63 mg, 1.25 mg/3 mL (levalbuterol)	nebulization of 1 vial (3 mL) three times daily	3 vials (3 mL each)	24 vials (3 mL each) per carton	4 packages (96 vials x 3mL) / 25 days 12 packages (288 vials x 3 mL) / 75 days
			25 vials (3 mL each) per carton	4 packages (100 vials x 3 mL) / 25 days 12 packages (300 vials x 3 mL) / 75 days
			30 vials (3 mL each) per carton	3 packages (90 vials x 3 mL) / 25 days 9 packages (270 vials x 3 mL) / 75 days
Xopenex Concentrate 1.25 mg/0.5 mL (levalbuterol)	nebulization of 1 vial (0.5 mL) three times daily	3 vials (0.5 mL each)	30 vials (0.5 mL each) per carton	3 packages (90 vials x 0.5 mL) / 25 days 9 packages (270 vials x 0.5 mL) / 75 days

Beta Agonists-Short Acting, Combination Oral Inhalation Limit Policy 1086-H 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-584281 021423

Xopenex HFA (levalbuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 15 gm canister	2 packages (15 gm each) / 25 days 6 packages (15 gm each) / 75 days
<i>*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.</i>				

REFERENCES

1. Airsupra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2023.
2. Albuterol sulfate inhalation solution 0.63 mg/3 mL and 1.25 mg/3 mL [package insert]. Columbia, SC: Ritedose Pharmaceuticals, LLC; May 2022.
3. Albuterol sulfate inhalation solution 0.083% [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; December 2021.
4. Albuterol sulfate inhalation solution, 0.5% (0.5 mL) [package insert]. West Columbia, SC: Nephron Pharmaceuticals Corporation; January 2021.
5. Albuterol sulfate inhalation solution, 0.5% (20mL) [package insert]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; February 2017.
6. Levalbuterol inhalation solution [package insert]. Memphis, TN: NorthStar Rx LLC; February 2023.
7. Levalbuterol solution, concentrate [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; October 2022.
8. ProAir Digihaler [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; December 2022.
9. ProAir HFA [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; September 2022.
10. ProAir Respiclick [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; September 2022.
11. Proventil HFA [package insert]. Princeton, NJ: Sandoz Inc.; December 2020.
12. Ventolin HFA [package insert]. Research Triangle Park, NC: GlaxoSmithKline; August 2021.
13. Xopenex inhalation solution [package insert]. Lake Forest, IL: Akorn, Inc.; December 2018.
14. Xopenex inhalation solution concentrate [package insert]. Lake Forest, IL: Akorn, Inc.; December 2018.
15. Xopenex HFA [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; February 2017.